AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10, Fidelity Earnings reports. AEterna Zentaris had a return on equity of 87.85% and a net margin of 34.40%. The business had revenue of $0.66 million during the quarter.
Shares of AEZS stock opened at $2.06 on Thursday. AEterna Zentaris has a 12-month low of $1.12 and a 12-month high of $3.25. The company has a market capitalization of $38.96 million, a P/E ratio of -1.53 and a beta of 0.75.
A number of equities analysts recently issued reports on AEZS shares. ValuEngine lowered AEterna Zentaris from a “hold” rating to a “sell” rating in a report on Friday, August 10th. Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating and three have given a buy rating to the stock. AEterna Zentaris presently has an average rating of “Buy” and an average price target of $3.25.
TRADEMARK VIOLATION WARNING: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://sportsperspectives.com/2018/11/08/aeterna-zentaris-aezs-issues-earnings-results-beats-estimates-by-0-10-eps.html.
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
See Also: Fundamental Analysis
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.